Cancer Research New Funding Opportunities

Gabrielle’s Angel Foundation is committed to funding innovative, translational proposals and to supporting promising independent early-career investigators, who are applying novel and state-of-the-art techniques to address fundamental problems in the genesis and treatment of blood-related cancers.  Projects will be funded for a three-year period at $75,000.00 per year.

As of 2019, the foundation accepts applications from both assistant professors and associate professors for integrative applications only.

The Dan L Duncan Comprehensive Cancer Center is invited to submit one or two nominees for this award. If interested, please upload a one-page letter of intent for the project and current NIH biosketch to the DLDCCC Proposal/LOI Submission Form by Thursday, July 4, 2024. The letter of intent will be used by the DLDCCC appointed review panel to make a final decision on the nominations.

For questions, contact the DLDCCC grants team.

The Dan L Duncan Comprehensive Cancer Center is seeking to fund one to two one-year pilot projects up to $50,000 each.

The focus for Duncan Pilot Projects for this announcement is cancer and the environment. We are particularly interested in: 

• Projects focused on cancers that have been identified as catchment area priorities. See the COE section of DLDCCC website for more information.
• Collaborative projects between DLDCCC members

Applications must be submitted by 5 p.m. on Monday, July 15, 2024.

All cancer center members who have a faculty appointment are eligible to apply. Indirect costs are not allowed, and applications do not need to be submitted via BRAIN. Please review the full descriptions in the attached RFA, as well as the provided Application Format and Instructions.

To apply, upload all the application requirements as a single PDF file to: DLDCCC Proposal Submission Form. For questions, contact the DLDCCC grants team.

The Dan L Duncan Comprehensive Cancer Center is seeking to fund up to three one-year pilot projects up to $50,000 each.

The focus of Duncan Pilot Projects for this announcement is Immunotoxicity in Cancer.

We are particularly interested in

• Projects focused on cancers that have been identified as catchment area priorities - See the COE section of DLDCCC website for more information.
• Collaborative projects between DLDCCC members

Applications should be submitted by 5 p.m. on Thursday, July 18, 2024.

All cancer center members who have a faculty appointment are eligible to apply. Indirect costs are not allowed, and applications do not need to be submitted via BRAIN.

To apply, upload all the application requirements as a single PDF file to: DLDCCC Proposal Submission Form. For questions, contact Carl Allen.

Purpose: The DLDCCC seeks to catalyze the development of collaborative research that will seed multi-PI R01-type grants at BCM. Ideally, this program is designed to facilitate interactions among two faculty who have not previously worked together to forge new collaborations to accelerate discovery.

Funding: The DLDCCC will fund up to 4 groups with up to $100,000 for one year.

Structure: The objective is for two principal investigators to work together on a common goal to generate preliminary data, and develop a collaborative relationship, that will eventually formulate the basis of a new R01-type cancer-related application. At least one of the PIs should be an Assistant Professor independent for no more than 7 years from the time of application submission.

Review: The DLDCCC will utilize a standing review committee to consider applications. The two PIs should not yet have a funded or published collaborative project, but collaborative work may have been recently initiated. In addition to standard NIH criteria (significance, approach etc.) the review committee will look for potential for future joint funding. Work in all areas of cancer research typically supported by the NCI will be considered.

Applications: Each application should include 1 collaborative Project and be assembled as one PDF in the following order:

1. 1 page overview including title, name and affiliations of involved PIs and abstract (100 words max).
2. Specific Aims with brief rationale and plan for collaboration (max 2 pages), plus separate references if needed).
3. Statement about the nature of the collaboration, including the collaborative history, the contribution of both PIs to the proposed project, and how this will lead to future funding opportunities. ½ page max.
4. Biosketches of PIs (standard NIH format)
5. Budget – 1 page – indicating distribution of funds to the two participating labs
6. Brief budget justification – maximum 1 page

Awarded projects will be expected to spend the funds within 1 year with a possible extension depending on progress/justification. Programs should be gearing toward submitting an R01 or similar within 12-18 months of the Mini-CiRCA award.

PIs may be involved in more than one collaborative application.

Submission: Applications should be submitted through the DLDCCC Proposal Submission Portal. The deadline is 5 p.m. Aug. 19, 2024. Funding is expected to commence on or around Oct. 1, 2024.

Questions about the RFA to “Julia” Juhee Hong or Chris Horaist. 

Translational research is a major priority of the Dan L Duncan Comprehensive Cancer Center and this RFA seeks to fund new collaborations between laboratory and clinical investigators to promote translation of findings from DLDCCC laboratories to clinical testing.

For this RFA we invite applications where there is a basic and clinical PI, with the goal of developing or optimizing a clinical protocol.

Research projects eligible for this award are:

1. Research aimed at translation of a scientific finding in a DLDCCC laboratory to a clinical trial.
2. Research aimed at optimizing a clinical strategy.

Eligible projects will:

1. Have two project leaders with one a laboratory scientist and one a clinical investigator
2. Both leaders must be DLDCCC members
3. The project may target any cancer, but we encourage applications that target catchment area cancers or cancers where there are fewer open clinical trials.
4. Provide a timeline to show translation is feasible within one year
5. Proposals involving simple large sample acquisition or data analysis from existing trials will not be supported
6. Proposals from current breast or lymphoma SPORE key personnel will not be supported as they have other mechanisms for translational support

Budgets of up to 100K for one year may be requested.

Review Criteria will include:

1. Strength of the scientific rationale and degree of innovation
2. Feasibility of proposal
3. Likelihood of translation to the clinic and obtaining subsequent funding
4. Relevance to DLDCCC strategic goals and catchment area issues

Applications should be submitted through the DLDCCC Proposal Submission Portal by 5 p.m. Aug. 12, 2024 and include:

1. Specific Aims – 1 page
2. Research Plan including Background, Innovation and Research Strategy – 3 pages
3. Timeline – 1 page
4. Budget justification – 1 page
5. NIH Bio sketches for project leaders

Proposals will be reviewed by the DLDCCC Research Review Committee who will recommend applications for funding to the DLDCCC Executive Committee. The funding will be for $100K per year with feasibility of extension by an additional $50K based on progress at the end of year.

The deadline for the submissions is 5 p.m. Aug. 12, 2024. The applications will be reviewed, and funding will be provided by Oct. 1, 2024.